Prolonged Diabetic Ketoacidosis Associated with Canagliflozin

Overview

Journal Endocrinol Diabetes Metab Case Rep

Specialty Endocrinology

Date 2018 Jun 15

PMID 29899991

Citations 6

Authors

Gordon Sloan

Tania Kakoudaki

Nishant Ranjan

Affiliations

Soon will be listed here.

Abstract

Learning Points: Diabetic ketoacidosis (DKA) may develop in the presence of lower-than-expected blood glucose levels in patients treated with a sodium glucose co-transporter 2 (SGLT-2) inhibitor.Certain individuals prescribed with SGLT-2 inhibitors may be more at risk of DKA, for example, those with a low beta cell function reserve, excessive alcohol consumption and a low carbohydrate diet.In order to reduce the risk of SGLT-2 inhibitor-associated DKA, all patients must be carefully selected before prescription of the medication and appropriately educated.Increased serum ketone levels and glucosuria have been reported to persist for several days despite discontinuation of their SGLT-2 inhibitor.Physicians should consider individualised treatment regimens for subjects with prolonged DKA in the presence of SGLT-2 inhibition.

Citing Articles

Revisiting Diabetic Ketoacidosis (DKA) Fluid Management: Should Normal Saline Be Used?.

Messina N, Anderson Z, Saravis L, Jimenez G, Plowman K, Harrington D Cureus. 2025; 17(1):e77739.

PMID: 39981474 PMC: 11839305. DOI: 10.7759/cureus.77739.

Repositioning Canagliflozin for Mitigation of Aluminium Chloride-Induced Alzheimer's Disease: Involvement of TXNIP/NLRP3 Inflammasome Axis, Mitochondrial Dysfunction, and SIRT1/HMGB1 Signalling.

Elariny H, Kabel A, Selim H, Helal A, Abdelrahman D, Borg H Medicina (Kaunas). 2024; 60(11).

PMID: 39596990 PMC: 11596744. DOI: 10.3390/medicina60111805.

Risk of diabetic ketoacidosis of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and network meta-analysis of randomized controlled trials.

Yang S, Liu Y, Zhang S, Wu F, Liu D, Wu Q Front Pharmacol. 2023; 14:1145587.

PMID: 37397500 PMC: 10311413. DOI: 10.3389/fphar.2023.1145587.

Severe Prolonged SGLT2i-induced Euglycemic Diabetic Ketoacidosis Refractory to Standard Therapy and Dialysis: Case Report and Literature Review.

Almazrouei R, AlKindi F, AlShamsi A, Dawoud T, Chaaban A, Rahman M Oman Med J. 2022; 37(3):e373.

PMID: 35712376 PMC: 9188737. DOI: 10.5001/omj.2022.17.

Prolonged ketosis and glycosuria secondary to SGLT2 inhibitor therapy.

Bobrowski D, Kumar R, Wu P, Lapointe-Shaw L Clin Case Rep. 2021; 9(11):e05057.

PMID: 34786197 PMC: 8577244. DOI: 10.1002/ccr3.5057.

References

Qiu H, Novikov A, Vallon V . Ketosis and diabetic ketoacidosis in response to SGLT2 inhibitors: Basic mechanisms and therapeutic perspectives. Diabetes Metab Res Rev. 2017; 33(5). DOI: 10.1002/dmrr.2886. View

Handelsman Y, Henry R, Bloomgarden Z, Dagogo-Jack S, DeFronzo R, Einhorn D . AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON THE ASSOCIATION OF SGLT-2 INHIBITORS AND DIABETIC KETOACIDOSIS. Endocr Pract. 2016; 22(6):753-62. DOI: 10.4158/EP161292.PS. View

Laffel L . Ketone bodies: a review of physiology, pathophysiology and application of monitoring to diabetes. Diabetes Metab Res Rev. 2000; 15(6):412-26. DOI: 10.1002/(sici)1520-7560(199911/12)15:6<412::aid-dmrr72>3.0.co;2-8. View

Ferrannini E, Baldi S, Frascerra S, Astiarraga B, Heise T, Bizzotto R . Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes. Diabetes. 2016; 65(5):1190-5. DOI: 10.2337/db15-1356. View

Fralick M, Schneeweiss S, Patorno E . Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. N Engl J Med. 2017; 376(23):2300-2302. DOI: 10.1056/NEJMc1701990. View

Adachi J, Inaba Y, Maki C . Euglycemic Diabetic Ketoacidosis with Persistent Diuresis Treated with Canagliflozin. Intern Med. 2017; 56(2):187-190. PMC: 5337465. DOI: 10.2169/internalmedicine.56.7501. View

Farjo P, Kidd K, Reece J . A Case of Euglycemic Diabetic Ketoacidosis Following Long-term Empagliflozin Therapy. Diabetes Care. 2016; 39(10):e165-6. DOI: 10.2337/dc16-0728. View

Candelario N, Wykretowicz J . The DKA that wasn't: a case of euglycemic diabetic ketoacidosis due to empagliflozin. Oxf Med Case Reports. 2016; 2016(7):144-6. PMC: 4962888. DOI: 10.1093/omcr/omw061. View

Andrews T, Cox R, Parker C, Kolb J . Euglycemic Diabetic Ketoacidosis with Elevated Acetone in a Patient Taking a Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitor. J Emerg Med. 2016; 52(2):223-226. DOI: 10.1016/j.jemermed.2016.07.082. View

10.

Kelmenson D, Burr K, Azhar Y, Reynolds P, Baker C, Rasouli N . Euglycemic Diabetic Ketoacidosis With Prolonged Glucosuria Associated With the Sodium-Glucose Cotransporter-2 Canagliflozin. J Investig Med High Impact Case Rep. 2017; 5(2):2324709617712736. PMC: 5468766. DOI: 10.1177/2324709617712736. View

11.

Pujara S, Ioachimescu A . Prolonged Ketosis in a Patient With Euglycemic Diabetic Ketoacidosis Secondary to Dapagliflozin. J Investig Med High Impact Case Rep. 2017; 5(2):2324709617710040. PMC: 5446101. DOI: 10.1177/2324709617710040. View

12.

Roach P, Skierczynski P . Euglycemic Diabetic Ketoacidosis in a Patient With Type 2 Diabetes After Treatment With Empagliflozin. Diabetes Care. 2015; 39(1):e3. DOI: 10.2337/dc15-1797. View

13.

Ferrannini E, Solini A . SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012; 8(8):495-502. DOI: 10.1038/nrendo.2011.243. View

14.

Hayami T, Kato Y, Kamiya H, Kondo M, Naito E, Sugiura Y . Case of ketoacidosis by a sodium-glucose cotransporter 2 inhibitor in a diabetic patient with a low-carbohydrate diet. J Diabetes Investig. 2015; 6(5):587-90. PMC: 4578500. DOI: 10.1111/jdi.12330. View

15.

Neal B, Perkovic V, Matthews D . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(21):2099. DOI: 10.1056/NEJMc1712572. View

16.

Gelaye A, Haidar A, Kassab C, Kazmi S, Sinha P . Severe Ketoacidosis Associated with Canagliflozin (Invokana): A Safety Concern. Case Rep Crit Care. 2016; 2016:1656182. PMC: 4819091. DOI: 10.1155/2016/1656182. View

17.

Savage M, Dhatariya K, Kilvert A, Rayman G, Rees J, Courtney C . Joint British Diabetes Societies guideline for the management of diabetic ketoacidosis. Diabet Med. 2011; 28(5):508-15. DOI: 10.1111/j.1464-5491.2011.03246.x. View

18.

Scheen A . Pharmacokinetics, Pharmacodynamics and Clinical Use of SGLT2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Clin Pharmacokinet. 2015; 54(7):691-708. DOI: 10.1007/s40262-015-0264-4. View

19.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

20.

Monami M, Nreu B, Zannoni S, Lualdi C, Mannucci E . Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. Diabetes Res Clin Pract. 2017; 130:53-60. DOI: 10.1016/j.diabres.2017.04.017. View